(lp0
S'CytRx Granted Type B Pre-NDA Meeting with US FDA for Registration Pathway with ... PR Newswire  - Jan 4, 2017 LOS ANGELES, Jan. 4, 2017 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, today announced that,&nbsp;...'
p1
aS'CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common ... PR Newswire  - Dec 13, 2016 LOS ANGELES, Dec. 13, 2016 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into securities purchase agreements with existing&nbsp;...'
p2
aS'CytRx to Present at the 29th Annual ROTH Conference PR Newswire  - Mar 7, 2017 LOS ANGELES, March 7, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...'
p3
aS'CytRx Appoints Chief Medical Officer Dr. Daniel Levitt as Chief Operating Officer PR Newswire  - Dec 19, 2016 LOS ANGELES, Dec. 19, 2016 /PRNewswire/ -- CytRx Corporation , a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing new therapeutics to treat patients with cancer, has appointed Daniel&nbsp;...'
p4
aS'CytRx to Present at the 19th Annual BIO CEO &amp; Investor Conference PR Newswire  - Feb 6, 2017 LOS ANGELES, Feb. 6, 2017 /PRNewswire/ -- CytRx Corporation , a biopharmaceutical research and development company specializing in oncology, today announced that Chairman and CEO Steven A. Kriegsman and David Haen, Vice&nbsp;...'
p5
aS'CytRx Corporation  Is A Top Contrarian Play Insider Financial - Oct 14, 2016 CytRx Corporation  has been the subject of some serious hit pieces over the last couple of months, on the back of the company announcing what was construed as disappointing results from an ongoing trial of its lead candidate,&nbsp;...'
p6
aS"CytRx: Aldoxorubicin Phase 3 Clinical Trial, Saddle Up Partner! Seeking Alpha - Jul 17, 2016 Can the retail investor survive any longer than a second line malignant cancer therapy patient in today's biotechnology market environment?"
p7
aS'CytRx Corporation  Soars 5.15% on March 20 Equities.com - Mar 20, 2017 CytRx Corporation  had a good day on the market for Monday March 20 as shares jumped 5.15% to close at $0.42. About 825,181 shares traded hands on 1,703 trades for the day, compared with an average daily volume of 1.37 million shares out of a&nbsp;...In focus: CytRx Corporation  Trading Patterns - Post AnalystAttention Grabbing Stocks: Morgan Stanley , SAP SE (NYSE:SAP ... - KC Register'
p8
aS'CytRx: The BASIC Chemistry Seeking Alpha - Oct 26, 2016 This article is meant to explain the general science of CytRx  and why they will continue to fail. We go over basic chemistry of &quot;pH sensitive linkers&quot; - the fundamental platform of CytRx. Further, we want to make it clear that although ...'
p9
aS'Is the Options Market Predicting a Spike in CytRx Corp  Stock? Nasdaq - Dec 30, 2016 Clearly, options traders are pricing in a big move for CytRx Corp shares, but what is the fundamental picture for the company?'
p10
a.